Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series
Safety profile observed in pediatric participants similar to previously reported data in adult participants
Pediatric...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Lyme Disease | Pediatrics | Pfizer | Pharmaceuticals | Study | Vaccines